ReviewGlycoconjugate journal2014
Regulation of cancer metabolism by O-GlcNAcylation.
Review in Glycoconjugate journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Recent development of analytical methods for disease-specific proteinRSC advances · 2022Review
- Chemistry-Assisted Proteomic Profiling of O-GlcNAcylation.Frontiers in chemistry · 2021Review
- Roles of the hexosamine biosynthetic pathway and pentose phosphate pathway in bile acid-induced cancer development.Cancer science · 2019Article
- Thio-Linked UDP-Peptide Conjugates as O-GlcNAc Transferase Inhibitors.Bioconjugate chemistry · 2018Article
- O-linked N-acetylglucosamine transferase promotes cervical cancer tumorigenesis through human papillomaviruses E6 and E7 oncogenes.Oncotarget · 2016Article
- Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer.Clinical and experimental medicine · 2015Article
- O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth.Nature communications · 2015Article
- The potential role of O-GlcNAc modification in cancer epigenetics.Cellular & molecular biology letters · 2014Review
- Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer.Frontiers in endocrinology · 2014Review
- Proteomic approaches for site-specific O-GlcNAcylation analysis.Bioanalysis · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells exhibit increased uptake of glucose and glutamine, and rewire the metabolic flux toward anabolic pathways important for cell growth and proliferation. Understanding how this altered metabolism is regulated has recently emerged as an intense research focus in cancer biology. O-linked β-N-acetylglucosamine (O-GlcNAc) is a reversible posttranslational modification of serine and/or threonine residues of nuclear and cytosolic proteins. O-GlcNAcylation has been identified in numerous proteins that are involved in many important cellular functions, including transcription, translation, signal transduction, and stress responses. More recently, increasing evidence indicates that O-GlcNAcylation plays important roles in regulating cancer metabolic reprogramming by modifying key transcription factors, metabolic enzymes and major oncogenic signaling pathways. Thus, O-GlcNAcylation emerges as a novel regulatory mechanism linking altered metabolism to cancer pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.